Clinical Trial Update: Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial update on low-dose interleukin-2 treatment for chronic spontaneous urticaria is reported, with current status undisclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Second Xiangya Hospital of Central South University | Conditions: Chronic Spontaneous Urticaria | Phase 2, Phase 3 | Status: UNKNOWN